Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers.
Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers.
复制标题
DOI：
10.1371/journal.pone.0046000
复制
发表时间：
2012
期刊：
影响因子：
3.7
通讯作者：
Molnár B
中科院分区：
文献类型：
--
作者：
Tóth K;Sipos F;Kalmár A;Patai AV;Wichmann B;Stoehr R;Golcher H;Schellerer V;Tulassay Z;Molnár B
甲基化Septin 9（SEPT 9）是来自外周血的结直肠癌（CRC）的敏感生物标志物。然而，其与癌症定位、基于愈创木脂的粪便潜血试验（gFOBT）和癌胚抗原（CEA）的关系尚未被描述。从结肠镜检查前无疾病证据（NED）（n =92）和手术治疗前CRC（n=92）的患者中采集血浆样本用于SEPT 9分析。 分离DNA并使用Epi proColon试剂盒2.0进行亚硫酸氢盐转化。使用Epi proColon 2.0 RT-PCR测定进行定性测定。从NED（分别为n = 17和27）和CRC（分别为n = 22和27）采集用于gFOBT和CEA分析的样本。 SEPT 9检测在NED和CRC中的阳性率分别为15.2%（14/92）和95.6%（88/92），其中II期至IV期CRC的阳性率为100%（67/67），I期CRC的阳性率为84%（21/25）。在第二次分析中（3次PCR重复中的2次），NED的特异性提高至99%（91/92），CRC中SEPT 9阳性的灵敏度为79.3%（73/92）。NED和CRC中gFOBT阳性率分别为29.4%（5/17）和68.2%（15/22），CEA阳性率分别为14.8%（4/27）和51.8%（14/27）。SEPT 9（84.8%）和CEA（85.2%）的特异性均高于gFOBT（70.6%）。SEPT 9在左半结肠癌（LSCC）和右半结肠癌（RSCC）中的阳性率分别为96.4%（54/56）和94.4%（34/36）。喉鳞状细胞癌和喉鳞状细胞癌gFOBT阳性率分别为83.3%（10/12）和50%（5/10），CEA阳性率分别为60%（9/15）和41.7%（5/12）。血浆中SEPT 9的高度敏感性和特异性使其成为比gFOBT和CEA更好的检测CRC的方法，即使对于更难检测的RSCC。
Methylated Septin 9 (SEPT9) is a sensitive biomarker for colorectal cancer (CRC) from peripheral blood. However, its relationship to cancer localization, guaiac-based fecal occult blood test (gFOBT) and carcinoembryonic antigen (CEA) have not been described. Plasma samples were collected for SEPT9 analysis from patients with no evidence of disease (NED) (n = 92) before colonoscopy and CRC (n = 92) before surgical treatment. DNA was isolated and bisulfite-converted using Epi proColon kit 2.0. Qualitative determination was performed using Epi proColon 2.0 RT-PCR assay. Samples for gFOBT and CEA analysis were collected from NED (n = 17 and 27, respectively) and CRC (n = 22 and 27, respectively). SEPT9 test was positive in 15.2% (14/92) of NED and 95.6% (88/92) of CRC, including 100% (67/67) from stage II to stage IV CRC and 84% (21/25) of stage I CRC when a sample was called positive if 1 out of 3 PCR replicates was positive. In a second analysis (2 out of 3 PCR replicates) specificity improved to 99% (91/92) of NEDs, at a sensitivity of 79.3% (73/92) of SEPT9 positives in CRC. gFOBT was positive in 29.4% (5/17) of NED and 68.2% (15/22) of CRC and elevated CEA levels were detected in 14.8% (4/27) of NED and 51.8% (14/27) of CRC. Both SEPT9 (84.8%) and CEA (85.2%) showed higher specificity than gFOBT (70.6%). SEPT9 was positive in 96.4% (54/56) of left-sided colon cancer (LSCC) cases and 94.4% (34/36) of right-sided colon cancer (RSCC) cases. gFOBT was positive in 83.3% (10/12) of cases with LSCC and 50% (5/10) of cases with RSCC, elevated CEA was detected 60% (9/15) of LSCC and 41.7% (5/12) of RSCC. The high degree of sensitivity and specificity of SEPT9 in plasma makes it a better method to detect CRC than gFOBT and CEA, even for the more difficult to detect RSCC.
登录
查看更多内容
影响因子：
9.3
作者：
Lofton-Day, Catherine;Model, Fabian;Sledziewski, Andrew
通讯作者：
Sledziewski, Andrew
影响因子：
6.3
作者：
Ghazi, Sam;Lindforss, Ulrik;Papadogiannakis, Nikos
通讯作者：
Papadogiannakis, Nikos
影响因子：
7.3
作者：
Kapiteijn, E;Liefers, GJ;van Krieken, JHJM
通讯作者：
van Krieken, JHJM
影响因子：
3.7
作者：
Gruetzmann, Robert;Molnar, Bela;Pilarsky, Christian;Habermann, Jens K.;Schlag, Peter M.;Saeger, Hans D.;Miehlke, Stephan;Stolz, Thomas;Model, Fabian;Roblick, Uwe J.;Bruch, Hans-Peter;Koch, Rainer;Liebenberg, Volker;deVos, Theo;Song, Xiaoling;Day, Robert H.;Sledziewski, Andrew Z.;Lofton-Day, Catherine
通讯作者：
Lofton-Day, Catherine
DOI：
10.1056/nejmoa0800996
发表时间：
2008-09-18
期刊：
The New England journal of medicine
影响因子：
--
作者：
Johnson CD;Chen MH;Toledano AY;Heiken JP;Dachman A;Kuo MD;Menias CO;Siewert B;Cheema JI;Obregon RG;Fidler JL;Zimmerman P;Horton KM;Coakley K;Iyer RB;Hara AK;Halvorsen RA Jr;Casola G;Yee J;Herman BA;Burgart LJ;Limburg PJ
通讯作者：
Limburg PJ